Diaceutics

Collaboration Opportunity: EMQN CIC Oncopanel EQA program

Recent therapeutic developments in NGS are revolutionizing biomarker detection in oncology however, only a slow transition towards the use of comprehensive genomic assessment has been observed irrespective, of the fact that many labs are equipped with these NGS platforms.

Why join the collaboration:

- Diaceutics sponsored enrollment onto the Oncopanel 20 EQA module. This program is being offered for labs using high throughput technologies (e.g., NGS, MassArray etc) to help accurately validate assay sensitivity and specificity. Click here for further details
- Gain confidence from an ISO:17043 accredited external body that NGS testing is being performed consistently and to a high standard.
- Benchmark yourself against peers who are also enrolled in this module
- Contribute insight to support publication of a white paper article that focuses on day to day considerations that influence NGS adoption for clinical testing purposes

Additional information

To be eligible to participate in this collaboration please ensure that:

- Ab profile information reflects:
- Lab assay details reflecting
 - - EGFR
 - BRAF
 - KRAS
 - MET (including ex14 skipping)
 - NTRK fusions
 - · RET fusions and mutations



Collaboration process











Issue primary surveyGathering of insights to support publication of white paper article





Enrolment for the 2021 Oncopanel module is active from 21st September 2020 to 31st March 2021. Please note that this collaboration may close early if the maximum number of participants has been met before the 31st March 2021. Should you be interested in this collaboration, we recommend that the lab profile and assay information is completed as soon as possible, as per defined requirements, to ensure your participation in this

Discover DXRX Collaborations

